Potential for Erroneous Results Indicating Resistance When Using the Bactec MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide

被引：93
作者：
Chedore, Pamela [1 ]
Bertucci, Lina [1 ]
Wolfe, Joyce [2 ]
Sharma, Meenu [2 ]
Jamieson, Frances [1 ]
机构：
[1] Ontario Agcy Hlth Protect & Promot, Publ Hlth Lab, Toronto, ON M9P 3T1, Canada
[2] Canadian Sci Ctr Human & Anim Hlth, Natl Microbiol Lab, Natl Reference Ctr Mycobacteriol, Winnipeg, MB, Canada
来源：
JOURNAL OF CLINICAL MICROBIOLOGY | 2010年 / 48卷 / 01期
关键词：
PNCA; MUTATIONS;
D O I：
10.1128/JCM.01775-09
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
During susceptibility testing of 743 isolates of Mycobacterium tuberculosis to pyrazinamide (PZA) using the Bactec 960 system, 57 (7.7%) isolates showed PZA resistance. Repeat testing of resistant isolates with the Bactec 460 reference method confirmed 33 (4.4%) of these isolates as resistant, and 24 (3.2%) were susceptible. Erroneous results for resistance with the Bactec 960 were confirmed by testing the 24 discordant isolates for pyrazinamidase and mutations in the pncA gene.
引用
收藏
页码：300 / 301
页数：2
相关论文
共 15 条
  • [1] Evaluation of BACTEC MGIT 960 PZA medium for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide (PZA):: compared with the results of pyrazinamidase assay and Kyokuto PZA test
    Aono, A
    Hirano, K
    Hamasaki, S
    Abe, C
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (04) : 347 - 352
  • [2] Becton Dickinson and Company, 1999, BACT MGIT 960 SYST U
  • [3] CLARK RB, 2009, CUMITECH 31A VERIFIC, P14
  • [4] *CLSI NCCLS, 2003, M24A CLSINCCLS, V23
  • [5] Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis
    Davies, AP
    Billington, OJ
    McHugh, TD
    Mitchison, DA
    Gillespie, SH
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (10) : 3686 - 3688
  • [6] Multicenter evaluation of the fully automated Bactec MGIT 960 system for susceptibility testing of Mycobacterium tuberculosis to pyrazinamide:: comparison with the radiometric Bactec 460TB system
    Kontos, F
    Nicolaou, S
    Kostopoulos, C
    Gitti, Z
    Petinaki, E
    Maniati, M
    Anagnostou, S
    Raftopoulou, A
    Papageorgiou, P
    Scrioubellou, A
    Tselentis, I
    Maniatis, AN
    [J]. JOURNAL OF MICROBIOLOGICAL METHODS, 2003, 55 (01) : 331 - 333
  • [7] Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis
    Mestdagh, M
    Fonteyne, PA
    Realini, L
    Rossau, R
    Jannes, G
    Mijs, W
    De Smet, KAL
    Portaels, F
    Van den Eeckhout, E
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) : 2317 - 2319
  • [8] Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis
    Morlock, GP
    Crawford, JT
    Butler, WR
    Brim, SE
    Sikes, D
    Mazurek, GH
    Woodley, CL
    Cooksey, RC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) : 2291 - 2295
  • [9] Laboratory diagnostic aspects of drug resistant tuberculosis
    Parsons, LM
    Somoskövi, A
    Urbanczik, R
    Salfinger, M
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 : 2086 - 2105
  • [10] Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system
    Pfyffer, GE
    Palicova, F
    Rüsch-Gerdes, S
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (05) : 1670 - 1674
12